Recursion Pharmaceuticals (RXRX) Stock Price

Financial Performance

The financial performance of Recursion Pharmaceuticals indicates a mixed trend. The company has managed to increase its revenue by an impressive 226.9% from the previous quarter and maintain a modest year over year growth of 2.3%. However, the gross profit shows a negative value, which is quite concerning as it indicates that the company's cost of goods sold is higher than their total revenue. Also, there's been a significant decrease in operating income profit by -90.3% year over year.

Stock Price

The stock price has shown a downward trend with a decline of -18.2% in the last month and -32.4% YoY. The RSI value at 41.33 suggests that the stock is neither oversold nor overbought, while its current trading price is lower than its 200-day moving average indicating bearish sentiment among investors.

Alternative Data Signals

The alternative data signals present another mixed picture for Recursion Pharmaceuticals' stock performance outlook. Website traffic trends show a minor dip (-5.1%) MoM suggesting slightly reduced online interest in the company or its offerings; however, this could be due to multiple factors beyond investor interest alone such as marketing activities or website changes etc., so should not be taken as definitive on its own.
The number of job postings have decreased by -16.7% MoM which could suggest slowing growth or cost-saving measures being implemented.
Employee business outlook remains neutral at around 52%, but it's worth noting that this has seen some improvement (up by 4%) compared to previous months.
On social media platforms like Twitter and Facebook, follower count has seen substantial increases (82.3%, and 46.2% respectively in the last 90 days) which could indicate growing public interest or successful marketing efforts.

Conclusion

In conclusion, while Recursion Pharmaceuticals has shown some positive signals like revenue growth and increased social media following, there are several concerning factors such as negative gross profit, declining stock price and reduced job postings. Therefore, the overall outlook for Recursion Pharmaceuticals' stock is bearish.

Note: This AI Stock Analysis is based on data as of September 27. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $5.52, will... Sign up to access price prediction.